TY - JOUR
T1 - Systematic review of amifostine for the management of oral mucositis in cancer patients
AU - Nicolatou-Galitis, Ourania
AU - Sarri, Triantafyllia
AU - Bowen, Joanne
AU - Di Palma, Mario
AU - Kouloulias, Vassilios E.
AU - Niscola, Pasquale
AU - Riesenbeck, Dorothea
AU - Stokman, Monique
AU - Tissing, Wim
AU - Yeoh, Eric
AU - Elad, Sharon
AU - Lalla, Rajesh V.
N1 - Funding Information:
Disclosures The Mucositis Guidelines Update was sponsored by Helsinn Healthcare S.A., Switzerland and BioAlliance Pharma, France. Per MASCC policy, no industry representatives had any role in the development of the guidelines.
PY - 2013/1
Y1 - 2013/1
N2 - Purpose: The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. Results: Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. Conclusion: Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment setting for this purpose. Additional well-designed research is needed to clarify the role of amifostine as an intervention for oral mucositis.
AB - Purpose: The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. Results: Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. Conclusion: Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment setting for this purpose. Additional well-designed research is needed to clarify the role of amifostine as an intervention for oral mucositis.
KW - Amifostine
KW - Guidelines
KW - Oral mucositis
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=84874110209&partnerID=8YFLogxK
U2 - 10.1007/s00520-012-1613-6
DO - 10.1007/s00520-012-1613-6
M3 - Review article
C2 - 23052919
AN - SCOPUS:84874110209
SN - 0941-4355
VL - 21
SP - 357
EP - 364
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 1
ER -